Psyence Biomed
Psyence Biomedical Ltd. (NASDAQ:PBM) is a Nasdaq-listed company with its subsidiary, The Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in Neuroplastogens-based therapeutics, the manufacture of pharmaceutical-grade drug candidates and conducting Clinical Trials. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived Neuroplastogens treatments across a range of mental health disorders.
Psyence Biomed
The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Our
Mission
Pioneering the use of natural
psychedelics for mental health
We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by an experienced entrepreneur Jody Aufrichtig (CEO) with Dr. Neil Maresky, a physician, as Global Head of Clinical Development. Dr Maresky has over 3 decades of experience in launching 50 NCE’s. Our expertise in intellectual property, capital markets and business development brings a global track record of sustainable growth and shareholder value.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by an experienced entrepreneur Jody Aufrichtig (CEO) with Dr. Neil Maresky, a physician, as Global Head of Clinical Development. Dr Maresky has over 3 decades of experience in launching 50 NCE’s. Our expertise in intellectual property, capital markets and business development brings a global track record of sustainable growth and shareholder value.
Our News
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
Our News
Psyence Biomed Study Featured on TV Channel 9 News Australia
Psyence BioMed, in collaboration with Southern Star Research, has been featured on Channel 9 News Australia for our role in advancing clinical research into the use of psilocybin-assisted psychotherapy for cancer patients experiencing emotional distress.
Corporate Update – August 2025
Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. These developments reflect not only a shift in our momentum but also a broader evolution of the company.
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
Psyence Biomed is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract.